Albemarle (ALB) Given News Impact Score of 0.09

Media coverage about Albemarle (NYSE:ALB) has been trending somewhat positive on Wednesday, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Albemarle earned a coverage optimism score of 0.09 on Accern’s scale. Accern also gave press coverage about the specialty chemicals company an impact score of 45.429919181621 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Here are some of the news stories that may have effected Accern’s rankings:

A number of brokerages have issued reports on ALB. Seaport Global Securities reissued a “buy” rating on shares of Albemarle in a report on Tuesday, March 6th. Royal Bank of Canada lowered their target price on shares of Albemarle from $133.00 to $100.00 and set a “buy” rating on the stock in a report on Friday, March 2nd. BMO Capital Markets reaffirmed an “outperform” rating and issued a $130.00 price target (down previously from $160.00) on shares of Albemarle in a report on Friday, March 2nd. Loop Capital set a $130.00 price target on shares of Albemarle and gave the stock a “buy” rating in a report on Friday, March 2nd. Finally, Nomura decreased their price target on shares of Albemarle from $161.00 to $141.00 and set a “buy” rating on the stock in a report on Thursday, March 1st. Eight research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $128.07.

Shares of ALB stock traded up $2.15 during trading hours on Wednesday, reaching $97.47. 1,780,347 shares of the company traded hands, compared to its average volume of 2,517,621. Albemarle has a one year low of $90.49 and a one year high of $144.99. The stock has a market capitalization of $10,721.97, a price-to-earnings ratio of 203.07, a PEG ratio of 1.17 and a beta of 1.60. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.06 and a quick ratio of 1.57.

Albemarle (NYSE:ALB) last announced its earnings results on Tuesday, February 27th. The specialty chemicals company reported $1.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.21 by $0.13. Albemarle had a net margin of 1.79% and a return on equity of 13.27%. The company had revenue of $857.79 million during the quarter, compared to analyst estimates of $791.46 million. equities analysts predict that Albemarle will post 5.11 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Monday, April 2nd. Investors of record on Thursday, March 15th will be given a $0.335 dividend. The ex-dividend date is Wednesday, March 14th. This is a positive change from Albemarle’s previous quarterly dividend of $0.32. This represents a $1.34 annualized dividend and a yield of 1.37%. Albemarle’s payout ratio is 279.17%.

TRADEMARK VIOLATION WARNING: “Albemarle (ALB) Given News Impact Score of 0.09” was first published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this story on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright legislation. The original version of this story can be accessed at

About Albemarle

Albemarle Corporation is a global developer, manufacturer and marketer of highly-engineered specialty chemicals. The Company operates through three segments: Lithium and Advanced Materials, Bromine Specialties and Refining Solutions. Lithium and Advanced Materials segment consist of two product categories: Lithium and Performance Catalyst Solutions.

Insider Buying and Selling by Quarter for Albemarle (NYSE:ALB)

Receive News & Ratings for Albemarle Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albemarle and related companies with's FREE daily email newsletter.

Leave a Reply